JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares S&P 500 Value ETF
IVE
|
+$2.05B |
| 2 |
iShares S&P 500 Growth ETF
IVW
|
+$1.92B |
| 3 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.13B |
| 4 |
iShares Russell 1000 Value ETF
IWD
|
+$1.1B |
| 5 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Japan ETF
BBJP
|
+$1.24B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$1.12B |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$989M |
| 4 |
Microsoft
MSFT
|
+$973M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$931M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.54% |
| 2 | Technology | 14.97% |
| 3 | Healthcare | 10.91% |
| 4 | Financials | 10.87% |
| 5 | Consumer Discretionary | 8.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ZEUS
4426
DELISTED
Olympic Steel
ZEUS
| $75K | ﹤0.01% |
7,178
-30,640
| -81% | -$411K |
2016 Q1
16 quarters
|
|
|
EXFO
4427
DELISTED
EXFO INC.
EXFO
| $75K | ﹤0.01% |
29,053
+700
| +2% | +$2.54K |
2015 Q4
17 quarters
|
|
|
GNMK
4428
DELISTED
GenMark Diagnostics, Inc
GNMK
| $75K | ﹤0.01% |
18,196
-870,394
| -98% | -$4.08M |
2013 Q2
27 quarters
|
|
4429
Lifecore Biomedical
LFCR
$248M
| $74K | ﹤0.01% |
8,498
+54
| +0.6% | +$562 |
2017 Q4
9 quarters
|
|
4430
Direxion Daily S&P 500 Bull 3x ETF
SPXL
$7.13B
| $74K | ﹤0.01% |
+2,836
| New | +$160K |
2020 Q1
0 quarters
|
|
|
TGA
4431
DELISTED
Transglobe Energy Corp
TGA
| $74K | ﹤0.01% |
204,702
-25,200
| -11% | -$26.4K |
2018 Q1
8 quarters
|
|
|
FPRX
4432
CALL
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $74K | ﹤0.01% |
+32,500
| New | +$138K |
2020 Q1
0 quarters
|
|
|
FPRX
4433
PUT
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $74K | ﹤0.01% |
+32,500
| New | +$138K |
2020 Q1
0 quarters
|
|
4434
Innovator US Equity Buffer ETF March
BMAR
$205M
| $73K | ﹤0.01% |
+3,075
| New | +$73.4K |
2020 Q1
0 quarters
|
|
4435
Gladstone Investment Corp
GAIN
$624M
| $73K | ﹤0.01% |
9,221
-6,056
| -40% | -$72K |
2019 Q4
1 quarter
|
|
|
LAND
4436
Gladstone Land Corp
LAND
$412M
| $73K | ﹤0.01% |
6,083
+19
| +0.3% | +$245 |
2016 Q2
15 quarters
|
|
|
STML
4437
DELISTED
Stemline Therapeutics, Inc.
STML
| $73K | ﹤0.01% |
15,085
+97
| +0.6% | +$629 |
2017 Q3
10 quarters
|
|
4438
Geron
GERN
$771M
| $72K | ﹤0.01% |
60,795
+391
| +0.6% | +$479 |
2014 Q4
21 quarters
|
|
4439
Innovator US Equity Power Buffer ETF March
PMAR
$748M
| $72K | ﹤0.01% |
+2,983
| New | +$72.5K |
2020 Q1
0 quarters
|
|
|
SOLY
4440
DELISTED
Soliton, Inc.
SOLY
| $72K | ﹤0.01% |
8,896
+1,765
| +25% | +$19.9K |
2019 Q2
3 quarters
|
|
|
CBIO
4441
Crescent Biopharma
CBIO
$532M
| $71K | ﹤0.01% |
311
+200
| +180% | +$76.4K |
2018 Q2
7 quarters
|
|
4442
PUT
Union Pacific
UNP
$165B
| $71K | ﹤0.01% |
500
-91,200
| -99% | -$15.1M |
2014 Q3
22 quarters
|
|
|
AFT
4443
DELISTED
Apollo Senior Floating Rate Fund Inc.
AFT
| $71K | ﹤0.01% |
6,126
| – | – |
2015 Q3
18 quarters
|
|
|
ALSK
4444
DELISTED
Alaska Communications Systems
ALSK
| $71K | ﹤0.01% |
+40,716
| New | +$77.9K |
2020 Q1
0 quarters
|
|
4445
PUT
Corbus Pharmaceuticals
CRBP
$119M
| $70K | ﹤0.01% |
447
| – | – |
2019 Q4
1 quarter
|
|
4446
ProShares Ultra Energy
DIG
$84.6M
| $70K | ﹤0.01% |
11,692
+11,680
| +97,333% | +$242K |
2019 Q3
2 quarters
|
|
|
MBII
4447
DELISTED
Marrone Bio Innovations, Inc.
MBII
| $70K | ﹤0.01% |
84,977
+17,108
| +25% | +$18.1K |
2018 Q2
7 quarters
|
|
|
FIT
4448
PUT
DELISTED
Fitbit, Inc. Class A common stock
FIT
| $70K | ﹤0.01% |
10,500
| – | – |
2019 Q4
1 quarter
|
|
|
TLRD
4449
DELISTED
Tailored Brands, Inc.
TLRD
| $70K | ﹤0.01% |
39,959
-865,599
| -96% | -$2.91M |
2016 Q1
16 quarters
|
|
4450
WisdomTree Europe SmallCap Dividend Fund
DFE
$162M
| $69K | ﹤0.01% |
1,700
| – | – |
2014 Q2
23 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2020 Portfolio in Review
As of Q1 2020, JP Morgan Chase held 6,012 positions worth $426B, down 21% from $536B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase deployed $14B of net new capital in Q1 2020, opening 362 new positions and adding to 2,382 existing holdings. Its largest new stake was NextEra Energy, Inc. 5.279% Corporate Units: 1,245,017 shares worth $54.9M.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, down from 28% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was JPMorgan BetaBuilders Japan ETF, an estimated $1.24B trimmed.
- JP Morgan Chase's largest Q1 2020 buy was NextEra Energy, Inc. 5.279% Corporate Units: 1,245,017 shares worth $54.9M.
- JP Morgan Chase added most to iShares S&P 500 Value ETF in Q1 2020, an estimated $2.05B increase.
- JP Morgan Chase's biggest Q1 2020 reduction was JPMorgan BetaBuilders Japan ETF, cutting an estimated $1.24B.
- JP Morgan Chase fully exited Liberty Property Trust in Q1 2020, selling an estimated $264M.
- JP Morgan Chase's ten largest holdings make up 18% of its $426B portfolio in Q1 2020.
- JP Morgan Chase opened 362 new positions and closed 692 in Q1 2020.
- JP Morgan Chase's portfolio value fell 21% quarter-over-quarter to $426B.
Based on JP Morgan Chase's 13F filing for Q1 2020, filed 12 May 2020.